Skip to main content
. Author manuscript; available in PMC: 2024 Oct 19.
Published in final edited form as: Pharmacol Ther. 2021 Mar 31;225:107844. doi: 10.1016/j.pharmthera.2021.107844

Fig. 3.

Fig. 3.

Summarized illustration of TCR engineered T cell approaches (A) targeting FLT3 neoantigen peptides; (B) Specific peptide enhanced affinity receptors (SPEARs) technology designed to modify the hypervariable complementary determining regions that bind to the displayed neoantigen peptide while simultaneously displaying no alloreactivity; (C) Hybrid murine-human TCR for better pairing and TCR/CD3 stability.